PreveCeutical Medical Inc (TSE:PREV)
:PREV
Want to see TSE:PREV full AI Analyst Report?
PREV Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.06
Previous CloseN/A
Volume100.00K
Average Volume (3M)143.42K
Market Cap
C$11.74M
Enterprise ValueC$16.40M
Total Cash (Recent Filing)C$10.24K
Total Debt (Recent Filing)C$4.68M
Price to Earnings (P/E)―
Beta-0.59
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding586,811,950
10 Day Avg. Volume276,937
30 Day Avg. Volume143,419
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
R&D And IP PipelineA clear emphasis on formulation, delivery platforms and early-stage therapeutic candidates with active IP progression provides durable optionality. Strong platform IP can enable licensing or partner commercialization, creating long-term value even before revenues emerge if patents and partnerships execute.
Exposure To Cannabinoid TherapeuticsSpecialization in cannabinoid-related therapeutics and drug delivery aligns the company with a structural growth area in health sciences. Long-term regulatory acceptance and increasing clinical interest in cannabinoid-enabled treatments can sustain addressable market growth for differentiated delivery solutions.
Lean Operating StructureA very small headcount implies a low fixed-cost base and focused R&D spend, which can meaningfully extend runway relative to larger peers. For a pre-revenue biotech, lean operations reduce near-term financing needs and help preserve capital for priority development milestones.
Bears Say
No Commercial Revenue And Persistent LossesNo commercial revenue across multiple years means the business model remains unvalidated and dependence on R&D milestones or partners is high. Persistent, worsening losses erode capital, limit reinvestment capacity, and increase the probability of dilution or halted programs absent new funding or successful partnerships.
Weak Balance Sheet And Rising DebtConsistent negative equity and increasing debt against a small asset base create elevated refinancing and solvency risk. This structural imbalance reduces financial flexibility, can force dilutive or costly recapitalizations, and constrains the company's ability to fund clinical progress or scale operations.
Accelerating Cash Burn And Weak Cash GenerationMaterial deterioration in operating cash flow and persistently negative free cash flow signal accelerating cash burn. The company remains dependent on external financing to continue development programs. That dependency is a lasting constraint, increasing funding risk and potential dilution in the medium term.
PreveCeutical Medical News
PREV FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was C$0.01 and its highest was C$0.06 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is C$11.74M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Jun 02, 2026 which is in 14 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
Currently, no data Available
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 586,811,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in TSE:PREV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―
Options Prices
Currently, No data available
---